Hounaida Mahfoud on Hemoperitoneum in Case of Type 3 VWD
Hounaida Mahfoud, Assistant Professor at Faculty of Medicine and Pharmacy of Rabat, shared on LinkedIn:
”Delighted to share the publication of our article on a difficult case managed successfully, thanks to my mentor Pr Mohamed El Khorassani and the dedicated ICU team at Hôpital de Maternité Souissi.
Honoured to be part of this work.
Hemoperitoneum secondary to a ruptured hemorrhagic C is usually a benign and self-limiting condition, but in women with type 3 von Willebrand disease (VWD), it may evolve into a severe and potentially life-threatening event due to the inability to achieve spontaneous hemostasis.
We report a case of a 30-year-old woman with type 3 VWD who presented with acute pelvic pain and profound anemia.
Transvaginal ultrasonography and MRI demonstrated a ruptured hemorrhagic ovarian cyst associated with a large hemoperitoneum.
Despite the extent of bleeding, the patient remained hemodynamically stable and was managed conservatively.
Treatment consisted of von Willebrand factor replacement, blood transfusion, analgesia, and close clinical and radiological monitoring.
Her condition improved progressively, with normalization of hemoglobin levels, resolution of symptoms, and significant regression of the hemoperitoneum on follow-up imaging.
No surgical intervention was required. Managing ovarian cyst rupture in severe VMD is particularly challenging, as surgical intervention carries substantial hemorrhagic risk.
Conservative management, when supported by adequate hemostatic therapy, can be both safe and effective, preserving ovarian function and reducing perioperative morbidity.
This case underscores the importance of individualized, multidisciplinary care to optimize management strategies in women with severe bleeding disorders.”
Read the full article here.
Article: Conservative Management of Hemoperitoneum Due to a Ruptured Hemorrhagic Ovarian Cyst in Type 3 von Willebrand Disease
Authors: Hounaida Mahfoud, Rim Laaboudi, Mohamed Elkhorassani, Nabil Elachhab, Samir Bargach
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch